(PULM) Pulmatrix, Inc. Business Model Canvas Research

Pulmatrix, Inc. depends on clinical research sites and investigators to run Phase 1b and other studies, where they enroll patients and generate the safety and efficacy data needed for respiratory and migraine programs.

These partners are critical because Pulmatrix is still advancing pipeline assets, so trial speed, data quality, and patient retention at each site directly shape readouts and next-step funding decisions.

• Patient data drives safety and efficacy readouts.
• Sites support respiratory and migraine studies.
• Trial execution affects pipeline progress.

Pulmatrix, Inc. needs manufacturing and formulation partners because iSPERSE is built for inhaled delivery, which requires tight control of particle size, dose uniformity, and quality. In clinical-stage development, these partners also support scale-up, stability testing, and GMP clinical supply so Pulmatrix, Inc. can move candidates through trials without building full in-house production.

• Enables inhalation dosing support
• Helps meet product quality standards
• Supports scale-up and clinical supply

Pulmatrix’s key activity is advancing two pipelines: Pulmazole for allergic bronchopulmonary aspergillosis and PUR3100 for acute migraine. That means running preclinical, clinical, and regulatory work across 2 distinct disease areas, which lowers single-asset risk and broadens the company’s shot at value creation.

• 2 programs: Pulmazole and PUR3100
• Respiratory plus neurology focus
• Needs preclinical, clinical, regulatory work

Pulmatrix, Inc. relies on licensing and alliance management to keep its external deals with RespiVert, Cipla, and Sensory Cloud on track. This means IP oversight, milestone checks, and partner coordination are core daily tasks, which is typical for a clinical-stage biotech where partnered programs can drive future value.

• Manage IP rights and contract terms
• Track development and payment milestones
• Coordinate closely with partners

Licensing activity is central because it links science to deal flow, and it can support cash use discipline while the pipeline is still in clinical development.

Pulmatrix's key resource is clinical and regulatory expertise: it needs deep trial design, safety monitoring, and FDA strategy to move inhaled assets through human testing. That know-how also helps it rank programs and frame partner talks around data, risk, and development path.

• Trial design and safety control
• Regulatory path to human studies
• Supports partner and program choices

Pulmatrix’s headquarters in Lexington, Massachusetts anchors its U.S. corporate base and supports management, R&D coordination, and business development. The site is the company’s main operating hub in fiscal 2025, centralizing decisions for a U.S.-listed biotech with one core headquarters.

• Lexington, Massachusetts headquarters
• Supports management and R&D coordination
• Drives business development from the U.S.

Pulmatrix’s pipeline spans three indications: fungal lung disease, COPD, and migraine. That gives it clinical diversification across distinct patient groups and lowers dependence on a single outcome or market.

• Three shots at value creation
• Different diseases, different risk pools
• Broader market optionality

iSPERSE is Pulmatrix, Inc.'s inhalation platform for both small and large molecule therapeutics, so it can widen the set of drugs that can be delivered to the lung. That breadth is the key value proposition: it can support multiple programs instead of relying on one asset, which is a clear edge versus single-asset biotech peers.

• Supports small and large molecules
• Expands inhaled drug options
• Reduces single-asset dependence

Pulmatrix, Inc. runs partner ties through licensing contracts and program milestones, so each step needs technical, legal, and business check-ins. In its latest filing, the Company still had no product sales, which shows this is a structured B2B model built on milestone delivery, not broad customer demand.

• Contract-led partner model
• Milestone tracking drives updates
• Technical, legal, business reviews
• Zero product revenue in latest filing

Pulmatrix, Inc. keeps investors informed through SEC filings, trial updates, and partnership news, so the market can track pipeline progress in real time. That steady disclosure matters for a small public biotech: as of the latest reported filings, the Company used 10-Q and 10-K updates to support access to capital and market trust.

• SEC filings: 10-Q and 10-K
• Shares trial and pipeline milestones
• Supports capital access

Pulmatrix, Inc. uses scientific updates and medical channels to reach researchers and clinicians, helping the platform and pipeline stay visible. Events like the ERS Congress draw 20,000+ respiratory specialists, so these channels matter for credibility, partner trust, and future uptake.

The cleaner the data and the more often it appears in peer-reviewed forums, the easier it is to support adoption. It also helps Pulmatrix, Inc. turn early science into deal interest and clinical confidence.

• Reach researchers and clinicians
• Build partner credibility
• Support pipeline awareness

Pulmatrix, Inc. uses corporate disclosures and investor-facing materials to keep capital markets visibility and show transparency. As a NASDAQ-listed biotech, it follows the standard SEC cadence of annual 10-K, quarterly 10-Q, and current 8-K filings, plus press releases and presentations.

• SEC filings drive disclosure
• Investor materials support visibility
• NASDAQ listing sets the channel norm

Acute migraine patients are a large, non-respiratory customer segment for Pulmatrix, Inc. PUR3100 targets rapid relief of migraine attacks through inhaled delivery, which can fit the same platform used in airway drugs but expands the addressable market beyond pulmonary care. Migraine affects about 1 in 7 people worldwide, so even modest uptake could add meaningful commercial upside.

• Fast-acting acute use case
• Inhaled platform, new market
• Large global patient pool

Pulmatrix, Inc. also sells to pharma and biotech partners that license or co-develop assets, so this segment includes development and commercialization counterparties. For a clinical-stage company, these partners matter because they can fund trials, share risk, and open a path to later-stage or commercial value.

• License and co-development partners
• Share clinical and commercial risk
• Key buyers for future value

Pulmatrix, Inc. bears legal, IP, and alliance-management costs for RespiVert, Cipla, and Sensory Cloud, so contract administration is a core operating task. In fiscal 2025, this cost line stayed tied to partner support, not scale production, which keeps it a steady cash burden.

It is a small but recurring drag: every amendment, filing, and review adds outside-counsel and admin spend.

• Legal and IP protection
• Alliance and contract admin
• Partner oversight for RespiVert, Cipla, Sensory Cloud

For Pulmatrix, Inc., general and administrative costs are the fixed overhead that keeps a public clinical-stage company running: management, finance, legal, HR, and SEC compliance. Public reporting adds recurring expense, and for a company with only a small operating base, these costs can still run in the low single-digit millions each year and stay material versus revenue.

• Public-company reporting drives recurring overhead.
• HQ staff covers finance, legal, and compliance.
• Fixed admin costs stay heavy at small scale.

If approved, Pulmazole, PUR1800, or PUR3100 could become Pulmatrix, Inc.'s first product sales, but this revenue stream depends on FDA success and a launch plan. As of FY2025, Pulmatrix had no commercial product sales, so this is still a future, not current, operating income source.

• Future sales need regulatory approval
• Commercial launch drives revenue timing
• No FY2025 product sales reported

Pulmatrix can earn royalties only if a partnered product reaches the market, so this stream can add high-margin, long-tail income without funding full commercialization. Royalty income is standard in biotech, and it can scale with sales after launch while Pulmatrix keeps cash outlay lower than building a full sales force.

• Starts after product launch
• High-margin, low-capex revenue
• Depends on partner sales